Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

Shire Basingstoke

Shire faces $650m loss on Dermagraft sale

Sells struggling foot ulcer treatment to Organogenesis

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

- PMLiVE

FDA approves GSK’s combo cancer treatment

US regulator backs Mekinist and Tafinlar to treat melanoma

- PMLiVE

J&J’s Imbruvica tops Arzerra in phase III trial

Shows improvement over GSK’s drug in haematological malignancies

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

EU flag

EC fines J&J and Novartis in pay-for-delay case

Says companies delayed entry of generic painkiller

- PMLiVE

Novartis’ Tasigna tops Glivec in long-term trial

Boost ahead of patent expiry for leukaemia drug

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

Novartis building

Novartis sets sights on eliminating leprosy

Throws weight behind meeting WHO's 2020 eradication goal

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links